Download PDF
Homœopathic Links 2022; 35(02): 093-100
DOI: 10.1055/s-0042-1755198
Proving

Hahnemann's Sick Proving: A Comprehensive Study on Its Working Methodology

Himanshu Sekhar Tiwary 
1   South Avenue C.G.H.S. Wellness Centre, Ministry of Health and Family Welfare, Govt. of India, New Delhi, India
,
Nidhi Tiwary
2   Consultant Homoeopathic Physician, New Delhi, India
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Background Homoeopathy operates with highly potentised medicines since, during sickness, there is a state of heightened sensitivity to similar stimuli in an individual. The same proposition is also the guiding principle behind one of the advanced methods of Hahnemann, i.e. sick proving. This tool was employed by Hahnemann in his later life to record the symptoms from sensitive and chronic patients. Unfortunately, this collateral method of drug proving has not been examined thoroughly and hence has not been utilised. This study intends to revisit Hahnemann's sick proving and decipher the finer shades of its working methodology.

Material and Methods A comprehensive literature search and analysis for sick proving was done from Hahnemann's major works such as Organon of Medicine, the Chronic Diseases, Materia Medica Pura and other literature such as lesser writings, redacted writings, letters, biographies and miscellaneous publications. All the proving records of the Chronic Diseases were examined in terms of their source and methodology and analysed from the perspective of sick proving.

Results From the present study, it has distinctly emerged that Hahnemann had a very systemic and methodical process of sick proving observed mainly in unaltering chronic patients. He used to take healthy drug proving symptoms mainly from other sources for his work in the Chronic Diseases and add symptoms from his sick proving as a collateral route. Sick proving was part of follow-up consultation in new as well as extensively proved drugs as evident from the Letter of Hermann Hartlaub in 1834. He added many valuable polychrest drugs in our armamentarium with the help of this method in his book the Chronic Diseases.

Conclusion Unlike healthy drug proving, sick proving by Hahnemann has not been thoroughly investigated despite its sound logic and tangible merits. A more detailed study is required to realise the full potential of this wonderful method of drug proving.

Keywords

sick proving - drug proving - chronic diseases - adverse drug reaction (ADR) - pharmacovigilance

Supplementary Material



Publication History

Article published online:
05 September 2022

© 2022. Thieme. All rights reserved.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bradford T. The Pioneers of Homoeopathy. Philadelphia: Boericke & Tafel; 1897: 5-10
    Google Scholar
  • 2 Haehl R. Life & Work of Samuel Hahnemann (2 Vols.). Vol. 2. New Delhi: B Jain Pub Pvt. Limited; 2003. : Supplement-61, page-105.
    Google Scholar
  • 3 Dinges M. Patients in the History of Homoeopathy. Sheffield: European Association for the History of Medicine and Health Publications; 2002: 7
    Google Scholar
  • 4 Robert J.. Samuel Hahnemann. The Founder of Homoeopathy translated by Margot Saar cited from Microsoft Word—Titlepage.doc (igm-bosch.de). Last visited-05–11–2021
    PubMedGoogle Scholar
  • 5 Hahnemann S. Materia Medica Pura. Vol. 1. New Delhi, India: Jain Publishers; ; reprint edition; 2004 preface p-2.
    Google Scholar
  • 6 Hahnemann S. The Chronic Diseases: Their Peculiar Nature and Their Homoeopathic Cure. New Delhi: B. Jain Publishers; (1999), prefaratory note to Materia Medica section by Richard Hughes page-xx
    Google Scholar
  • 7 Boger C. The Relation of Homoeopathy to Pathology; 1902
    PubMed
  • 8 Hahnemann S, Dudgeon RE. Lesser Writings of Samuel Hahnemann. Indian books& Periodicals Syndicate, New Delhi, (2007), Spirit of the Homoeopathic doctrine of medicine 1813, Reprint edition March 2007-page no.701 (footnote).
    PubMedGoogle Scholar
  • 9 Hahnemann S. Organon of Medicine, 5th & 6th Edition. New Delhi: B Jain Pub. Pvt. Limited; reprint edition 2008.
    Google Scholar
  • 10 Haehl RM. Life & Work of Samuel Hahnemann: Volume 2. New Delhi: B Jain Publishers Pvt Ltd. New Delhi; India; 2006. ; pp. 201
    Google Scholar
  • 11 Sharma B. Homoeopathic pathogenetic trial. Homœopathic Links 2019; 32 (03) 127-128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Manchanda R, Mehra P, Khurana A. et al. Homoeopathic drug proving researches (1996–2018): a scoping review. Indian Journal of Research in Homoeopathy 2020; 14 (01) 24 DOI: 10.4103/ijrh.ijrh_32_19.
    CrossrefPubMedGoogle Scholar
  • 13 World Health Organization. . (n.d.). Pharmacovigilance. World Health Organization. Accessed July 17, 2022, Retrieved February 16, 2022, from https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance
    PubMed
  • 14 Rabinovitz H, Berkowitch M, Golik A, Shani S. [Adverse drug reactions definitions and terminology]. Harefuah 2001; 140 (12) 1181-1186 , 1228
    PubMedGoogle Scholar
  • 15 Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc JL. French Association of PharmacoVigilance Centres. Trends of reporting of ‘serious’vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database. Br J Clin Pharmacol 2012; 74 (01) 201-204
    CrossrefPubMedGoogle Scholar